Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study

被引:0
作者
Flouri, Irini [1 ]
Goutakoli, Panagiota [2 ,3 ]
Repa, Argyro [1 ]
Bertsias, Antonios [1 ]
Avgoustidis, Nestor [1 ]
Eskitzis, Anastasios [1 ]
Pitsigavdaki, Sofia [1 ]
Kalogiannaki, Eleni [1 ]
Terizaki, Maria [1 ]
Bertsias, George [2 ,3 ]
Sidiropoulos, Prodromos [2 ,3 ]
机构
[1] Univ Crete, Med Sch, Rheumatol Clin Immunol & Allergy Dept, Iraklion, Greece
[2] Univ Crete, Med Sch, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[3] Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece
关键词
Tumor necrosis factor inhibitor; Rheumatoid arthritis; Axial spondyloarthritis; Psoriatic arthritis; Etanercept; Disease activity trajectories; Drug survival; NECROSIS-FACTOR INHIBITORS; ACTIVITY SCORE ASDAS; ANKYLOSING-SPONDYLITIS; DRUG SURVIVAL; SPONDYLOARTHRITIS; VALIDATION;
D O I
10.1007/s00296-023-05455-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observational study of RA, axial (AxSpA) and peripheral SpA (PerSpA) patients initiating etanercept during 2004-2020. Kaplan-Meier plots were used for drug retention comparisons and multivariable Cox regression models for predictors of discontinuation. Long-term disease activity trajectories were identified by latent class growth models using DAS28-ESR or ASDAS-CRP as outcome for RA and AxSpA respectively. We assessed 711 patients (450 RA, 178 AxSpA and 83 PerSpA) with a median (IQR) follow-up of 12 (5-32) months. At 5 years, 22%, 30% and 21% of RA, AxSpA and PerSpA patients, respectively, remained on therapy. Etanercept discontinuation was independent of the diagnosis and was predicted by gender and obesity in both RA and SpA groups. Four disease activity (DA) trajectories were identified from 6th month of treatment in both RA and AxSpA. RA patients in remission-low DA groups (33.7%) were younger, had shorter disease duration, fewer comorbidities and lower baseline disease activity compared to moderate (40.6%) & high DA (25.7%) groups. In AxSpA 74% were in inactive-low DA and they were more often males, non-obese and had lower number of comorbidities compared to higher ASDAS-CRP trajectories. In RA and AxSpA patients, disease activity trajectories revealed heterogeneity of TNFi treatment responses and prognosis. Male gender, lower baseline disease activity and fewer comorbidities, characterize a favourable outcome in terms of disease burden accrual and TNFi survival.
引用
收藏
页码:249 / 261
页数:13
相关论文
共 50 条
[1]   Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[2]   Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice [J].
Anderson, Jaclyn ;
Caplan, Liron ;
Yazdany, Jinoos ;
Robbins, Mark L. ;
Neogi, Tuhina ;
Michaud, Kaleb ;
Saag, Kenneth G. ;
O'Dell, James R. ;
Kazi, Salahuddin .
ARTHRITIS CARE & RESEARCH, 2012, 64 (05) :640-647
[3]   Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts [J].
Baganz, Lisa ;
Richter, Adrian ;
Albrecht, Katinka ;
Schneider, Matthias ;
Burmester, Gerd-Ruediger ;
Zink, Angela ;
Strangfeld, Anja .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (06) :976-982
[4]   Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study [J].
Bertsias, Antonios ;
Avgoustidis, Nestor ;
Papalopoulos, Ioannis ;
Repa, Argyro ;
Kougkas, Nikolaos ;
Kalogiannaki, Eleni ;
Bertsias, Georgios ;
Flouri, Irini ;
Sidiropoulos, Prodromos .
ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
[5]   Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months [J].
Bykerk, Vivian P. ;
Lee, Eun Bong ;
Vollenhoven, Ronald ;
Gruben, David C. ;
Fallon, Lara ;
Woolcott, John C. ;
Keystone, Edward .
ARTHRITIS CARE & RESEARCH, 2022, 74 (01) :131-141
[6]   Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9years of experience from the Rhumadata® clinical database and registry [J].
Choquette, Denis ;
Bessette, Louis ;
Alemao, Evo ;
Haraoui, Boulos ;
Postema, Roelien ;
Raynauld, Jean-Pierre ;
Coupal, Louis .
ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
[7]   Survival analysis part I: Basic concepts and first analyses [J].
Clark, TG ;
Bradburn, MJ ;
Love, SB ;
Altman, DG .
BRITISH JOURNAL OF CANCER, 2003, 89 (02) :232-238
[8]   Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study [J].
Courvoisier, D. S. ;
Alpizar-Rodriguez, D. ;
Gottenberg, J. E. ;
Hernandez, M. V. ;
Iannone, F. ;
Lie, E. ;
Santos, M. J. ;
Pavelka, K. ;
Turesson, C. ;
Mariette, X. ;
Choquette, D. ;
Hetland, M. L. ;
Finckh, A. .
EBIOMEDICINE, 2016, 11 :302-306
[9]   Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs [J].
Dagliati, Arianna ;
Plant, Darren ;
Nair, Nisha ;
Jani, Meghna ;
Amico, Beatrice ;
Peek, Niels ;
Morgan, Ann W. ;
Isaacs, John ;
Wilson, Anthony G. ;
Hyrich, Kimme L. ;
Geifman, Nophar ;
Barton, Anne .
ARTHRITIS & RHEUMATOLOGY, 2020, 72 (10) :1632-1642
[10]   Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis [J].
De Craemer, Ann-Sophie ;
Renson, Thomas ;
Deroo, Liselotte ;
Van Praet, Liesbet ;
Cypers, Heleen ;
Varkas, Gaelle ;
Joos, Rik ;
Devinck, Mieke ;
Gyselbrecht, Lieve ;
Peene, Isabelle ;
Thevissen, Kristof ;
Costantino, Felicie ;
D'Agostino, Maria-Antonietta ;
Lenaerts, Jan ;
Carron, Philippe ;
Van den Bosch, Filip ;
Elewaut, Dirk .
RHEUMATOLOGY, 2022, 61 (08) :3279-3288